For the year ending 2025-12-31, CLDX had $515K increase in cash & cash equivalents over the period. -$213,659K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -258,757 |
| Depreciation and amortization | 3,380 |
| Amortization and premium of marketable securities, net | 5,855 |
| Loss on disposal of assets | -12 |
| Stock-based compensation expense | 36,217 |
| Accounts and other receivables | 1,315 |
| Prepaid and other current assets | -8,706 |
| Other assets | 3,611 |
| Accounts payable and accrued expenses | 11,031 |
| Other liabilities | -753 |
| Net cash used in operating activities | -210,945 |
| Sales and maturities of marketable securities | 596,288 |
| Purchases of marketable securities | 384,502 |
| Acquisition of property and equipment | 2,714 |
| Net cash provided by (used in) investing activities | 209,072 |
| Proceeds from issuance of stock from employee benefit plans | 2,388 |
| Net cash provided by financing activities | 2,388 |
| Net increase (decrease) in cash and cash equivalents | 515 |
| Cash and cash equivalents at beginning of period | 28,356 |
| Cash and cash equivalents at end of period | 28,871 |
Celldex Therapeutics, Inc. (CLDX)
Celldex Therapeutics, Inc. (CLDX)